Marienhospital Bottrop

Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer Update Mammakarzinom 2024 Teil 3 – Patientinnen mit fortgeschrittenen Stadien des Mammakarzinoms (2025) Lüftner D, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer (2024) Fasching P, Hu C, Hart SN, Rübner M, Polley EC, Gnanaolivu RD, Hartkopf AD, et al. Journal article The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype (2024) Ziegler P, Hartkopf AD, Wallwiener M, Häberle L, Kolberg HC, Hadji P, Tesch H, et al. Journal article Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole (2024) Fasching P, Hack C, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, et al. Journal article Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry (2024) Hartkopf AD, Walter CB, Kolberg HC, Hadji P, Tesch H, Fasching P, Ettl J, et al. Journal article CDK4/6 Inhibition – Therapy Sequences and the Quest to Find the Best Biomarkers – an Overview of Current Programs (2024) Schneeweiss A, Brucker SY, Hübner H, Volmer LL, Hack C, Seitz K, Rübner M, et al. Journal article, Review article Update Breast Cancer 2024 Part 1 - Expert Opinion on Advanced Breast Cancer (2024) Würstlein R, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Schütz F, Fasching P, et al. Journal article Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective (2024) Krug D, Banys-Paluchowski M, Brucker SY, Denkert C, Ditsch N, Fasching P, Haidinger R, et al. Journal article, Review article Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care – The PreFace Study (2023) Hack C, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, et al. Journal article Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041) (2023) Fasching P, Hein A, Kolberg HC, Häberle L, Uhrig S, Rübner M, Belleville E, et al. Journal article